Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Climb Bio, Inc.'s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The filings cover operating and financial results, Regulation FD pipeline disclosures, material-event reports and capital-structure information for common stock listed under the symbol CLYM.
Company filings also describe budoprutug and CLYM116 development disclosures, financing arrangements, executive and accounting officer changes, and governance matters presented in proxy materials. Proxy disclosures address director elections, auditor ratification, charter amendments, equity incentive plan provisions, stockholder voting procedures and other annual meeting matters.
Climb Bio, Inc. furnished a current report to share that it issued a press release on November 6, 2025 announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to the report and is incorporated by reference. The company notes that this information is being furnished under the securities laws rather than treated as filed for liability purposes.
Climb Bio (CLYM) filed an 8-K announcing new long-term follow-up data for budoprutug, an anti‑CD19 monoclonal antibody in development for B‑cell mediated diseases. An abstract reports results from a previously conducted Phase 1b trial (NCT04652570) in primary membranous nephropathy.
The data showed long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Three patients required no further immunosuppressive treatment during follow-up. No treatment‑related adverse events grade 3 or higher were observed in the trial.
The company’s forward‑looking statements section references development plans for budoprutug and CLYM116 and outlines risks including clinical progress, regulatory approvals, competition, intellectual property, and capital needs.
Amendment No. 4 to a Schedule 13D updates holdings and recent sales by Access Industries affiliates in Climb Bio, Inc. The Reporting Persons collectively own 3,835,117 shares, equal to 5.66% of the 67,764,100 shares outstanding as of July 31, 2025. The filing notes the issuer changed its name from "Eliem Therapeutics, Inc." to "Climb Bio, Inc." and its Nasdaq symbol to CLYM, effective October 2, 2024. The amendment discloses open-market sales by AI ETI totaling 75,383 shares on September 25–29, 2025 at weighted average prices around $2.11 per share, and on October 3, 2025 sales of 1,101,900 shares including a 1,100,000-share block trade at $1.9501 per share. The filing states control relationships among AI ETI, Access Industries Holdings, Access Industries Management and Len Blavatnik and includes a joint filing agreement.
Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.
Climb Bio, Inc. filed an 8-K reporting an employment-related material event involving Susan Altschuller. The filing references an Offer Letter dated September 30, 2025 between Climb Bio and Dr. Altschuller and includes an electronic cover page in Inline XBRL dated October 1, 2025. The document also cites the company’s S-1 filed August 2, 2021, which contains an indemnification provision that may require the company to indemnify Dr. Altschuller for certain expenses (including attorneys’ fees), judgments, penalties, fines and settlement amounts reasonably incurred arising from her service to the company. The filing notes there are no family relationships between Dr. Altschuller and the company’s directors or officers.
Climb Bio, Inc. reported new preclinical results for its monoclonal antibody CLYM116, which targets APRIL and is being developed for IgA nephropathy. In a completed nonhuman primate study, CLYM116 showed deeper IgA reduction and a longer half-life compared with sibeprenlimab, a first-generation anti-APRIL antibody, suggesting a potential for less frequent dosing. Additional in vivo mouse studies showed enhanced APRIL elimination and antibody recycling versus sibeprenlimab.
The company plans, subject to regulatory clearance, to start a Phase 1 trial of CLYM116 in healthy volunteers in Q4 2025, with initial biomarker and dosing-interval data expected around mid-year 2026. Climb Bio is hosting a virtual investor event on September 29, 2025 to discuss these data, supported by a press release and presentation.
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.